Immunic Secures $400 Million to Fund Late-Stage Multiple Sclerosis Trials
news.keyFacts
- •Immunic secured up to $400 million in a private placement to support late-stage trials for its multiple sclerosis treatment.
- •$200 million has already been received, with the remainder available in a second tranche.
- •The funds will be used to complete trials for vidofludimus calcium and prepare for a potential commercial launch.
Immunic Inc (NASDAQ: IMUX) has successfully secured up to $400 million through a private placement to advance its clinical pipeline. The biotechnology company confirmed that $200 million has already been received, with the remaining balance accessible in a second tranche. These funds are specifically earmarked to complete late-stage trials for vidofludimus calcium, a promising treatment for multiple sclerosis. Beyond clinical milestones, the capital injection will support preparations for a potential commercial launch of the drug. CEO Dr. Daniel Vitt emphasized that this financing provides the necessary runway to reach critical Phase 3 objectives. This significant capital raise reduces financial risk for the company as it approaches pivotal data readouts.